Perioperative care for patients with rheumatic diseases

Bharath M Akkara Veetil, Tim Bongartz

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The perioperative care of patients with rheumatic diseases is hampered by a lack of evidence-based recommendations. Rheumatologists are called upon to 'clear' their patients for surgery, yet the evidence upon which to base decisions is fractionated and inconsistent. We have systematically reviewed the current literature and developed suggestions for three key areas that require particular deliberations in patients with rheumatic diseases scheduled for surgery: the management of cardiovascular risk, use of immunosuppressive drugs, and states of altered coagulation. For patients with rheumatic diseases associated with increased cardiovascular risk, such as rheumatoid arthritis and systemic lupus erythematosus, we suggest following the American College of Cardiologyĝ€"American Heart Association guidelines using the underlying disease as a risk modifier. Most evidence suggests a neutral effect of conventional DMARDs in the perioperative period, with no need to discontinue them prior to surgery. Conversely, we suggest minimizing perioperative steroid use and unnecessary 'steroid preps'. The potential benefits of discontinuing biologic drugs in the perioperative setting needs to be carefully balanced with the risks associated with a disease flare. We discuss the American College of Chest Physicians guidelines, which classify individuals with antiphospholipid antibody syndrome as high-risk patients for perioperative thrombosis who are likely to require bridging therapy in most perioperative settings.

Original languageEnglish (US)
Pages (from-to)32-41
Number of pages10
JournalNature Reviews Rheumatology
Volume8
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Perioperative Care
Rheumatic Diseases
Steroids
Guidelines
Perioperative Period
Antirheumatic Agents
Antiphospholipid Syndrome
Risk Management
Immunosuppressive Agents
Pharmaceutical Preparations
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Thrombosis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Perioperative care for patients with rheumatic diseases. / Veetil, Bharath M Akkara; Bongartz, Tim.

In: Nature Reviews Rheumatology, Vol. 8, No. 1, 01.2012, p. 32-41.

Research output: Contribution to journalArticle

Veetil, Bharath M Akkara ; Bongartz, Tim. / Perioperative care for patients with rheumatic diseases. In: Nature Reviews Rheumatology. 2012 ; Vol. 8, No. 1. pp. 32-41.
@article{1bad594bd3a44849bd1930ca7e38e319,
title = "Perioperative care for patients with rheumatic diseases",
abstract = "The perioperative care of patients with rheumatic diseases is hampered by a lack of evidence-based recommendations. Rheumatologists are called upon to 'clear' their patients for surgery, yet the evidence upon which to base decisions is fractionated and inconsistent. We have systematically reviewed the current literature and developed suggestions for three key areas that require particular deliberations in patients with rheumatic diseases scheduled for surgery: the management of cardiovascular risk, use of immunosuppressive drugs, and states of altered coagulation. For patients with rheumatic diseases associated with increased cardiovascular risk, such as rheumatoid arthritis and systemic lupus erythematosus, we suggest following the American College of Cardiologyĝ€{"}American Heart Association guidelines using the underlying disease as a risk modifier. Most evidence suggests a neutral effect of conventional DMARDs in the perioperative period, with no need to discontinue them prior to surgery. Conversely, we suggest minimizing perioperative steroid use and unnecessary 'steroid preps'. The potential benefits of discontinuing biologic drugs in the perioperative setting needs to be carefully balanced with the risks associated with a disease flare. We discuss the American College of Chest Physicians guidelines, which classify individuals with antiphospholipid antibody syndrome as high-risk patients for perioperative thrombosis who are likely to require bridging therapy in most perioperative settings.",
author = "Veetil, {Bharath M Akkara} and Tim Bongartz",
year = "2012",
month = "1",
doi = "10.1038/nrrheum.2011.171",
language = "English (US)",
volume = "8",
pages = "32--41",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Perioperative care for patients with rheumatic diseases

AU - Veetil, Bharath M Akkara

AU - Bongartz, Tim

PY - 2012/1

Y1 - 2012/1

N2 - The perioperative care of patients with rheumatic diseases is hampered by a lack of evidence-based recommendations. Rheumatologists are called upon to 'clear' their patients for surgery, yet the evidence upon which to base decisions is fractionated and inconsistent. We have systematically reviewed the current literature and developed suggestions for three key areas that require particular deliberations in patients with rheumatic diseases scheduled for surgery: the management of cardiovascular risk, use of immunosuppressive drugs, and states of altered coagulation. For patients with rheumatic diseases associated with increased cardiovascular risk, such as rheumatoid arthritis and systemic lupus erythematosus, we suggest following the American College of Cardiologyĝ€"American Heart Association guidelines using the underlying disease as a risk modifier. Most evidence suggests a neutral effect of conventional DMARDs in the perioperative period, with no need to discontinue them prior to surgery. Conversely, we suggest minimizing perioperative steroid use and unnecessary 'steroid preps'. The potential benefits of discontinuing biologic drugs in the perioperative setting needs to be carefully balanced with the risks associated with a disease flare. We discuss the American College of Chest Physicians guidelines, which classify individuals with antiphospholipid antibody syndrome as high-risk patients for perioperative thrombosis who are likely to require bridging therapy in most perioperative settings.

AB - The perioperative care of patients with rheumatic diseases is hampered by a lack of evidence-based recommendations. Rheumatologists are called upon to 'clear' their patients for surgery, yet the evidence upon which to base decisions is fractionated and inconsistent. We have systematically reviewed the current literature and developed suggestions for three key areas that require particular deliberations in patients with rheumatic diseases scheduled for surgery: the management of cardiovascular risk, use of immunosuppressive drugs, and states of altered coagulation. For patients with rheumatic diseases associated with increased cardiovascular risk, such as rheumatoid arthritis and systemic lupus erythematosus, we suggest following the American College of Cardiologyĝ€"American Heart Association guidelines using the underlying disease as a risk modifier. Most evidence suggests a neutral effect of conventional DMARDs in the perioperative period, with no need to discontinue them prior to surgery. Conversely, we suggest minimizing perioperative steroid use and unnecessary 'steroid preps'. The potential benefits of discontinuing biologic drugs in the perioperative setting needs to be carefully balanced with the risks associated with a disease flare. We discuss the American College of Chest Physicians guidelines, which classify individuals with antiphospholipid antibody syndrome as high-risk patients for perioperative thrombosis who are likely to require bridging therapy in most perioperative settings.

UR - http://www.scopus.com/inward/record.url?scp=84655169655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84655169655&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2011.171

DO - 10.1038/nrrheum.2011.171

M3 - Article

C2 - 22083219

AN - SCOPUS:84655169655

VL - 8

SP - 32

EP - 41

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 1

ER -